Literature DB >> 33226501

Intestinal microbiome: a new target for chalaziosis treatment in children?

Mariaelena Filippelli1, Roberto dell'Omo2, Angela Amoruso3, Ilaria Paiano2, Marco Pane3, Pasquale Napolitano2, Silvia Bartollino2, Ciro Costagliola2.   

Abstract

Intestinal dysbiosis (changes in the gut commensal microbiome) is related to several ophthalmic diseases. The aim of this study was to verify whether oral specific probiotics can alter the clinical course of chalaziosis and its recurrence. A prospective comparative pilot study involving 26 children suffering from chalaziosis was conducted. Children were randomly divided into two groups. The first group received medical treatment (lid hygiene, warm compression and dexamethasone/tobramycin ointment for at least 20 days), and the second group received medical treatment plus a daily supplementation of oral probiotics (≥ 1 × 10^9 live cells of Streptococcus thermophilus ST10 (DSM 25246), ≥ 1 × 10^9 live cells of Lactococcus lactis LCC02 (DSM 29536) and ≥ 1 × 10^9 live cells of Lactobacillus delbrueckii subsp. bulgaricus (DSM 16606) with maltodextrin as the bulking agent (Probiotical S.p.A., Novara, Italy). All patients were evaluated at 2-week intervals for 3 months. If the lesion had not disappeared or decreased in size to 1 mm or less in diameter at the time of subsequent visits, the same procedure was repeated for another 3-month cycle. There was a significant difference in the time taken for complete resolution of the chalazion between the two groups in favour of the children receiving the probiotics. The treatment was not associated with any significant complications in either group. Trial registration: The trial was registered at clinical trials.gov under NCT04322500 on 25/03/2020 ("retrospectively registered").Conclusions: Modification of the intestinal microbiome with specific probiotics can alter the clinical course of chalaziosis in children by re-establishing intestinal and immune homeostasis. Probiotic supplementation can increase the effectiveness of traditional therapies by prompting the complete resolution of chalaziosis in a shorter amount of time, in an easy and feasible way. What is Known: • The intestinal microbiome plays a crucial role in several inflammatory diseases of the eye and is considered a therapeutic target. • Probiotics play a role in the prevention and treatment of different conditions in children. What is New: • In children probiotic supplementation is safe and effective. • Probiotic supplementation reduced the time required for complete resolution of the chalazion.

Entities:  

Keywords:  Chalaziosis; Children; Microbiome; Probiotics

Mesh:

Year:  2020        PMID: 33226501     DOI: 10.1007/s00431-020-03880-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  30 in total

Review 1.  Relationship between the microbiome and ocular health.

Authors:  Kara M Cavuoto; Santanu Banerjee; Anat Galor
Journal:  Ocul Surf       Date:  2019-05-21       Impact factor: 5.033

Review 2.  Importance of the intestinal microbiota in ocular inflammatory diseases: A review.

Authors:  Phoebe Lin
Journal:  Clin Exp Ophthalmol       Date:  2019-03-25       Impact factor: 4.207

3.  Dysbiosis in the Gut Bacterial Microbiome of Patients with Uveitis, an Inflammatory Disease of the Eye.

Authors:  Sama Kalyana Chakravarthy; Rajagopalaboopathi Jayasudha; Gumpili Sai Prashanthi; Mohammed Hasnat Ali; Savitri Sharma; Mudit Tyagi; Sisinthy Shivaji
Journal:  Indian J Microbiol       Date:  2018-06-04       Impact factor: 2.461

4.  The good bugs: the use of probiotics in pediatrics.

Authors:  Naire Sansotta; Diego G Peroni; Simone Romano; Anna Rugiano; Pierluigi Vuilleumier; Giuseppe Baviera
Journal:  Curr Opin Pediatr       Date:  2019-10       Impact factor: 2.856

Review 5.  The role of the intestinal microbiome in ocular inflammatory disease.

Authors:  Phoebe Lin
Journal:  Curr Opin Ophthalmol       Date:  2018-05       Impact factor: 3.761

Review 6.  Does the microbiota play a role in the pathogenesis of autoimmune diseases?

Authors:  Mairi H McLean; Dario Dieguez; Lindsey M Miller; Howard A Young
Journal:  Gut       Date:  2014-11-21       Impact factor: 23.059

7.  Preliminary evidence of the efficacy of probiotic eye-drop treatment in patients with vernal keratoconjunctivitis.

Authors:  Alfonso Iovieno; Alessandro Lambiase; Marta Sacchetti; Barbara Stampachiacchiere; Alessandra Micera; Stefano Bonini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-11-27       Impact factor: 3.117

Review 8.  The influence of gut-derived CD39 regulatory T cells in CNS demyelinating disease.

Authors:  Javier Ochoa-Repáraz; Lloyd H Kasper
Journal:  Transl Res       Date:  2016-07-28       Impact factor: 7.012

9.  Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series.

Authors:  Bonnie A Sklar; Kalla A Gervasio; Siyang Leng; Arnab Ghosh; Ajai Chari; Albert Y Wu
Journal:  BMC Ophthalmol       Date:  2019-05-14       Impact factor: 2.209

Review 10.  Benefaction of probiotics for human health: A review.

Authors:  Rout George Kerry; Jayanta Kumar Patra; Sushanto Gouda; Yooheon Park; Han-Seung Shin; Gitishree Das
Journal:  J Food Drug Anal       Date:  2018-02-02       Impact factor: 6.157

View more
  3 in total

1.  Suggestions on gut-eye cross-talk: about the chalazion.

Authors:  Carla Enrica Gallenga; Marco Mura; Pier Enrico Gallenga
Journal:  Int J Ophthalmol       Date:  2022-09-18       Impact factor: 1.645

2.  Effectiveness of oral probiotics supplementation in the treatment of adult small chalazion.

Authors:  Mariaelena Filippelli; Roberto dell'Omo; Angela Amoruso; Ilaria Paiano; Marco Pane; Pasquale Napolitano; Giuseppe Campagna; Silvia Bartollino; Ciro Costagliola
Journal:  Int J Ophthalmol       Date:  2022-01-18       Impact factor: 1.779

Review 3.  Influence of gut microbiota on eye diseases: an overview.

Authors:  Pasquale Napolitano; Mariaelena Filippelli; Sergio Davinelli; Silvia Bartollino; Roberto dell'Omo; Ciro Costagliola
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.